Management and Prevention of Neutropenia Supportive Care

Neulasta Significantly Reduces Febrile Neutropenia Among Colorectal Cancer Patients Receiving Chemotherapy Plus Avasatin (02-25-2013)

Neulasta® (pegfilgrastim) significantly reduced the incidence of grade 3/4 febrile neutropenia among patients with locally advanced or metastatic colorectal cancer who received chemotherapy with FOLFOX or FOLFIRI followed by Avastin® (bevacizumab),... Continue Reading

Naproxen May Relieve Bone Pain Associated with Neulasta (08-2-2012)

Twice-daily naproxen is effective in reducing the incidence and severity of bone pain associated with the use of Neulasta® (pegfilgrastim), according to the results of a study published in the Journal of Clinical Oncology. Neulasta is a blood cell growth... Continue Reading

Celebrities Stand Up to Cancer (09-14-2009)

Celebrities and Amgen are joining forces to Stand Up to Cancer™—in the form of a public service campaign designed to educate cancer patients and caregivers about managing the increased risk of infection during cancer treatment. Chemotherapy is an... Continue Reading

Amgen Helps Reduce Out-of-pocket Costs for Neulasta® (07-3-2009)

Amgen’s Neulasta FIRST STEP™ Program provides assistance to eligible, low-income, commercially-insured chemotherapy patients who need help with their co-insurance or co-payment requirement for Neulasta® (pegfilgrastim). Neulasta is a blood cell growth... Continue Reading